Get the app
NSEHealthcare

SENORES PHARMACEUTICALS L (SENORES)

NSE · Healthcare · Drug Manufacturers - General

₹1,402.60+1.87%
Last close · 2026-09-17

Latest quarter · ended 2026-06-30

Revenue
₹180 cr
Revenue YoY
+38.3%
Net profit
₹31 cr
Profit YoY
+55.7%
EPS
₹6.60
EPS estimate
₹5.81
Net margin
17.0%

EPS came in at 6.60 against a street estimate of 5.81 — a beat of 13.6%.

Key statistics

Market cap
₹6,757 cr
P/E
51.5
Forward P/E
0.0
P/B
7.22
Book value
₹235.10
EPS (TTM)
₹28.47
52-week high
₹1,599.00
52-week low
₹662.45
50-day MA
₹1,432.30
200-day MA
₹1,036.25

Analyst view

with an average price target of ₹1,620.00.

Shareholding

Promoters
54.93%
Institutions
10.52%

Recent filings & reports

DocumentDate
Annual report FY2026
SENORES PHARMACEUTICALS LIMITED - ANNUAL REPORT 2025-26 SUMMARY HEADLINE NUMBERS • Market Capitalization (as of March 31, 2026): ₹3,490.40 Crores •
2026-09-03
Q1 FY27 earnings call
SENORES PHARMACEUTICALS LIMITED – Q1 FY27 SUMMARY HEADLINE NUMBERS • Consolidated revenue from operations: INR 180 crores (Q1 FY27), up 36% Y-o-Y •
2026-08-03
Investor presentation
SENORES PHARMACEUTICALS LIMITED – Q1 FY27 INVESTOR SUMMARY --- HEADLINE NUMBERS • Revenue Q1FY27: ₹180.2 Crs, up 36% Y-o-Y (Q1FY26: ₹132.6 Crs) •
2026-07-27
Q4 FY26 earnings call
SENORES PHARMACEUTICALS LIMITED – Q4 FY26 SUMMARY --- HEADLINE NUMBERS • FY26 Total Revenue: INR 664 crores (62% Y-o-Y growth vs FY25) • FY26 Profi
2026-05-19
Investor presentation · Q4 FY26
SENORES PHARMACEUTICALS LIMITED – INVESTOR SUMMARY HEADLINE NUMBERS • Total Income FY26: Rs. 664.0 crores, up 61.8% year-on-year (Q4FY26: Rs. 189.7
2026-05-14
Quarterly results · Q4 FY26
SENORES PHARMACEUTICALS LIMITED – FINANCIAL SUMMARY HEADLINE NUMBERS • Q4 FY26 Total Income: Rs. 190 Cr (+66% Y-o-Y) • Q4 FY26 EBITDA: Rs. 62 Cr (+2
2026-05-14
Q3 FY26 earnings call
SENORES PHARMACEUTICALS LIMITED – Q3FY26 SUMMARY HEADLINE NUMBERS • Q3FY26 consolidated revenue: INR175 crores (64% YoY growth) • 9MFY26 consolidate
2026-01-27
Investor presentation · Q3 FY26
SENORES PHARMACEUTICALS LIMITED – INVESTOR SUMMARY HEADLINE NUMBERS • Total Income Q3FY26: Rs. 174.6 crores (up 64% Y-o-Y from Rs. 106.4 crores) • T
2026-01-20

Readable in the app.

Deals & corporate news

AnnouncementDate
Company informed about acquisition updates
Senores Pharmaceuticals Limited has informed the Exchange regarding updates on acquisition
2026-01-16
Acquisition of another business or entity completed
Senores Pharmaceuticals Limited has informed the Exchange regarding Acquisition
2025-12-15

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for SENORES PHARMACEUTICALS L — free to start.

Google PlayApp Store

Other Healthcare companies

Data updated 2026-09-18.